A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)

Phase 1

• Conditions: Ewing Sarcoma; Low Grade Fibromyxoid Sarcoma; Extraskeletal Myxoid Chondrosarcoma; Desmoplastic Small Round Cell Tumor; Clear Cell Sarcoma; Myxoid Liposarcoma; Angiomatoid Fibrous Histiocytoma; Sclerosing Epithelioid Fibrosarcoma; Myoepithelial Tumor
• Interventions: Drug: Seclidemstat

• Registration Number: NCT05266196
• Lead Sponsor: Salarius Pharmaceuticals, LLC

Brief Summary

This rollover protocol allows continued access to seclidemstat (SP-2577) for patients who are still receiving clinical benefit on completed or closed Salarius sponsored studies.

Detailed Description

The population for the rollover study should be consistent with the population defined in the parent study. The primary eligibility criteria for a patient to enter the rollover protocol is the participation and completion of a Salarius sponsored study with seclidemstat. Safety data and an evaluation of anti-tumor activity will be collected.

Patients who have completed a prior study with seclidemstat and who are assessed by the Investigator to continue to benefit from ongoing treatment will be eligible.

Study Timeline

• Study First Submitted: 2021-11-11
• Study Start: 2022-01-15
• Study First Submitted QC: 2022-02-23
• Study First Posted: 2022-03-04
• Status Verified: 2023-07
• Last Update Submitted: 2023-07-31
• Last Update Posted: 2023-08-01
• Primary Completion: 2025-12
• Study Completion: 2025-12

Recruitment & Eligibility

• Status: ENROLLING_BY_INVITATION
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

1. Patient is currently enrolled in a Salarius-sponsored study that is approved to enroll into this rollover study, and are receiving seclidemstat as monotherapy or in combination with other study treatment per the parent protocol (i.e. topotecan and cyclophosphamide). The maximum time between discontinuing the parent protocol and starting this rollover protocol is 14 days.
2. Patient is currently benefiting from the treatment with seclidemstat monotherapy or combination treatment, as determined by the investigator
3. Patient has demonstrated compliance, as assessed by the investigator, with the parent study protocol requirements
4. Willingness and ability to comply with scheduled visits, treatment plans and any other study procedures
5. Ability to understand and the willingness to sign a written informed consent document.
6. Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of seclidemstat administration.

Read More

Exclusion Criteria

1. Patient has been permanently discontinued from study treatment in the parent study due to any reason, except for the purpose of entering this open label rollover study.
2. Pregnant and breastfeeding women are excluded from this study. The effects of seclidemstat on the developing human fetus have the potential for teratogenic or abortifacient effects. There is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with seclidemstat.
3. Patient is receiving prohibited concomitant therapy as described in Section 5.4.2 of the rollover protocol, or therapy not allowed in the parent protocol.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Single agent	Seclidemstat	Single agent seclidemstat, as assigned per parent protocol
TC Combination	Seclidemstat	Combination of seclidemstat with topotecan and cyclophosphamide, as assigned per parent protocol

Primary Outcome Measures

Name	Time	Method
Length of time receiving study treatment	months on study where patients continue to receive clinical benefit, up to 5 years	Length of time receiving treatment with seclidemstat as single agent or in combination with assigned parent protocol therapy

Secondary Outcome Measures

Name	Time	Method
Number of patients enrolled through study completion	Number of patients enrolled on study who continue to receive clinical benefit, up to 5 years	Number of patients enrolled who received seclidemstat
Evaluate anti-tumor activity based upon imaging studies according to RECIST v1.1	During treatment while on study and continuing to receive clinical benefit, up to 5 years	Evaluate the anti-tumor activity of seclidemstat based upon imaging studies according to RECIST v1.1
Evaluate safety & tolerability utilizing the most current version of CTCAE	During treatment while on study and continuing to receive clinical benefit, up to 5 years	Evaluate the safety and tolerability of seclidemstat by characterizing adverse events according to the most current version of CTCAE

Trial Locations

Locations (1)

Sarcoma Oncology Center; 🇺🇸 Santa Monica, California, United States